BRD2 and acute myeloid leukemia: We describe key mechanisms and applications of NATs, review pre-clinical and clinical examples of NATs as differentiation agents in myeloid leukemias, and provide NAT design and delivery strategies to modulate relevant AML therapeutic targets.